P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Titel:
P-249 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Auteur:
Angotti, L. Lucchetti, J. Cortellini, A. Basso, M. Polito, M. Zoratto, F. Di Giacomo, E. Calegari, M. Lo Prinzi, F. Gemma, D. Signorelli, C. Veroli, M. Trombetta, G. Guerriero, S. Muscio, L. Galbato Di Cocco, B. Schietroma, F. Anghelone, A. Vincenzi, B. Tonini, G.